Capitolis Liquid Global Markets’s Terns Pharmaceuticals TERN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$104M Sell
1,975,800
-1,069,400
-35% -$43.9M 0.66% 28
2025
Q4
$123M Buy
+3,045,200
New +$70.4M 0.73% 33

Other funds holding TERN

Capitolis Liquid Global Markets's TERN Position: Q1 2026 in Review

Capitolis Liquid Global Markets reduced its Terns Pharmaceuticals (TERN) stake by 35% in Q1 2026, selling an estimated $43.9M and leaving 1,975,800 shares worth $104M. The position accounts for 0.66% of the portfolio, ranked #28.

Capitolis Liquid Global Markets first reported a position in TERN in Q4 2025 and has held it in 2 quarters since. The position peaked at $123M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Capitolis Liquid Global Markets held 1,975,800 shares of Terns Pharmaceuticals worth $104M as of Q1 2026.
  • Capitolis Liquid Global Markets sold 1,069,400 Terns Pharmaceuticals shares in Q1 2026, an estimated $43.9M.
  • Terns Pharmaceuticals made up 0.66% of Capitolis Liquid Global Markets's portfolio in Q1 2026, its #28 holding.
  • Capitolis Liquid Global Markets first reported a position in Terns Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Capitolis Liquid Global Markets's Terns Pharmaceuticals position peaked at $123M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Capitolis Liquid Global Markets's 13F filing for Q1 2026, filed 15 May 2026.